New press release out: HCS Pharma participates in the development of an improved biomimetic liver model on chip for drug discovery

HCS Pharma announces the closure of the “MIMLIVERonChip” project, funded by the French National Research Agency (ANR, project ANR 19 CE19-0020) and coordinated by BMBI Biomechanics and Bioengineering joint research unit (UTC/ CNRS), headed by Dr Cécile Legallais, CNRS research director. This project led to the publication of Taha Messelmani’s Read more…

Feedback of Rania’s internship about the development of primary human hepatocyte model in biochip microfludic system

This is the end of Rania‘s 6-month internship in HCS Pharma about a new liver biochip system. After a first publication “Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix” in collaboration with the University of Technology of Compiègne (UTC) using the BIOMIMESYS® Liver hydroscaffold™ and HepG2/C3A (hepatocellular Read more…

HCS Pharma @ELRIG congress in Basel “Advancements in cell & gene therapy: new therapeutic horizons” on Friday, 15th september 2023

In HCS Pharma we strongly believe that 3D cell culture is the right way to improve drug dicovery processes. Moreover, we know that our 3D hydroscaffold matrix BIOMIMESYS® could be useful for bioproduction and then for cell therapy. We will be happy to meet you at ELRIG congress “Advancements in cell & Read more…

We are happy to give a presentation at ESTIV congress in Barcelona (21-25 November 2022)

Our Project Leader in in vitro pharmacology Méryl Roudaut will present his presentation entitled “A single procedure to generate functional hiPSCs-derived liver organoids – Towards an innovative tools suitable for drug screening” during the session: Early Stage Researcher Session I (Tuesday, November 22nd, 2022). Abstract #165: We previously showed that Read more…

Human liver organoids and disease models, it’s time to use a more realistic ECM

The current hiPSC-derived models are adapted to reproduce diseases of genetic origin in two dimensions and have allowed in recent years to model diseases by using hepatocyte-like-cells (HCL) such as: Alpha1-antitrypsin (A1AT) deficiency (Tafaleng et al., 2015) Familial transthyretin-related amyloidosis (ATTR) (Isono et al., 2014) Glycogen storage deficiency (Satoh et Read more…

A single procedure to generate functional hiPSCs-derived liver organoids -Towards an innovative tool suitable for drug screening

The current hiPSC-derived models are adapted to reproduce diseases of genetic origin. However, the current two-dimensional HLC (hepatocyte like-cells) model has an immature liver phenotype that is more is closer to a perinatal liver. Furthermore, it does not take into account the complexity of the tissues and the extracellular environment Read more…

Importance of the liver extracellular matrix in the development of NASH/ASH

The extracellular matrix (ECM) is a non-cellular component of tissues and organs. It is mainly composed of structural elements (proteoglycans collagens, elastin) and cell adhesion proteins such as fibronectin and laminins. The ECM forms a complex structure with physical properties (elasticity, tensile and compression strength), which provides physical support for Read more…